Advertisement

Picture Berlin Partner Top News CRIPSR Repairs Immune Cells 650x100px
Organisation › Details

Pulmocide Ltd.

Pulmocide Ltd (www.pulmocide.com) is a late-stage biopharmaceutical company developing novel therapies for patients suffering from serious acute and chronic respiratory diseases. Pulmocide’s lead product is PC945, a novel antifungal specifically designed for inhaled use to maximise the amount of drug in the lung and spare systemic exposure. This is expected to provide for superior efficacy against respiratory aspergillosis while minimizing systemic toxicities. PC945 is expected to be useful in a variety of conditions where Aspergillus has been implicated. *

 

Period Start 2013-11-21 established (approx)
Products Industry respiratory drug delivery technology
  Industry 2 anti-infective drug
Persons Person Rapeport, William Garth (Pulmocide Ltd 201311– CEO before RespiVert CEO + co-founder)
  Person 2 Strong, Pete (Pulmocide Ltd 201311– CSO before co-founder of Respivert)
     
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 44 Southampton Buildings
  City WC2A 1AP London
  Tel +44-203-763-9484
    Address record changed: 2021-05-29
     
Basic data Employees n. a.
     
    * Document for »About Section«: Pulmocide Ltd.. (5/27/21). "Press Release: Pulmocide Raises $92 Million in a Series C Financing to Fund Registration Program for PC945". London.
     
   
Record changed: 2023-07-10

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Pulmocide Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top